Cantor Fitzgerald lowered the firm’s price target on uniQure (QURE) to $47 from $58 and keeps an Overweight rating on the shares following the Q2 earnings report. The main update from the earnings call is that the statistical analysis plan for AMT-130 in Huntington’s disease has been submitted, the analyst tells investors in a research note. Cantor thinks the September data could be a strong catalyst that could help to make the case that this therapy could be approved.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure Reports Q2 2025 Progress and Financials
- uniQure price target lowered to $35 from $38 at Chardan
- Mizuho defends uniQure, says factors why it is down are ‘non-issues’
- uniQure’s Strategic Advancements and Regulatory Progress Lead to Buy Rating
- Positive Outlook for uniQure’s AMT-130 Program Amidst Upcoming 3-Year Data Release